Digitisation | August 10, 2021
Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The drug is indicated for mild and transient episodes of heart block
Subscribe To Our Newsletter & Stay Updated
